Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey
Authors:
- On Behalf Of The In Focus Delphi Working PartyOPOn Behalf Of The In Focus Delphi Working Party
- Arun V. KrishnanAKArun V. Krishnan
- Kate WebberKWKate Webber
- Lisa HorvathLHLisa Horvath
- 7 June 2017
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 25 (11) , 3485-3493
Abstract
Background/purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a prominent side effect of the treatment of cancer. Despite this frequent complication, there has been no comprehensive review and quality appraisal of CIPN assessments. The purpose of this study is to provide a definitive quality appraisal of CIPN assessment strategies for clinical use. Methods Relevant studies were identified through database searches of Medline, Embase, CINAHL, and Cochrane. CIPN assessment strategies from included articles were extracted and initially rated by an oncologist and neurophysiologist according to criteria related to assessment depth, comprehensiveness, appropriateness, and reliability. The six highest scoring assessment strategies were the focus of a two-round Delphi survey of a working party of 32 physicians, nurses, and consumers to achieve consensus on the highest rated assessments for each criterion. Results The database search yielded 117 distinct CIPN assessments that were extracted from 2373 articles. Three patient-reported outcome surveys and three clinician-based assessments were included in the Delphi survey. No consensus was generated regarding the best overall CIPN assessment, although good (≥70%) consensus was achieved regarding the best assessment within each criterion. The Participant Neurotoxicity Questionnaire (PNQ) was rated the highest overall and patient-reported outcome (PRO) assessment, while the Total Neuropathy Score clinical version (TNSc) was the highest rated clinician-based assessment. Conclusions A diverse range of CIPN assessments currently exists. While several assessments assess CIPN symptoms with adequate comprehensiveness, depth, language, and feasibility, the consensus ‘gold standard’ clinical assessment remains to be established.Keywords
Funding Information
- Cancer Institute NSW (14/TPG/1-05)
- National Health and Medical Research Council (1080521, 1037746)
This publication has 37 references indexed in Scilit:
- Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathyMuscle & Nerve, 2016
- The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of FallingJAMA Neurology, 2016
- Measures of chemotherapy‐induced peripheral neuropathy: a systematic review of psychometric propertiesJournal of the Peripheral Nervous System, 2010
- Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapyBreast Cancer Research and Treatment, 2010
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Fe‐deration of Neurological Societies and the Peripheral Nerve SocietyEuropean Journal of Neurology, 2010
- Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategiesEuropean Journal of Cancer, 2008
- The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity ScaleJournal of the Peripheral Nervous System, 2007
- Distal symmetric polyneuropathy: A definition for clinical researchNeurology, 2005
- Grading of chemotherapy-induced peripheral neuropathyAnnals of Oncology, 2000
- Total neuropathy scoreNeurology, 1999